Apimeds Pharmaceuticals US (APUS) Gains from Investment Securities (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Gains from Investment Securities came in at -$12859.0 in Q3 2025, down 35.1% on a QoQ basis from -$9518.0 in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Gains from Investment Securities (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 1 years of Gains from Investment Securities data on file, last reported at -$12859.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Apimeds Pharmaceuticals US | 7.68 Mn | 7.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -12,859.00 |
| Sep 30, 2025 | -12,859.00 |
| Jun 30, 2025 | -9,518.00 |
| Jun 30, 2025 | -9,518.00 |